Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Withdrawn × Eflornithine × Clear all

Phase

Phase 3 1 Phase 2 1

Status

Completed 8 Recruiting 5 Withdrawn 1 Not yet recruiting 1 Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Interventions

pembrolizumab 49 Radiotherapy 46 Cisplatin 38 Paclitaxel 36 Gemcitabine 35 Cyclophosphamide 34 Carboplatin 32 Dexamethasone 31 Nivolumab 30 Fluorouracil 29 Docetaxel 28 Bevacizumab 28 Oxaliplatin 26 Leucovorin 23 Rituximab 22 Magnetic Resonance Spectroscopy 22 durvalumab 21 Capecitabine 20 Drug Therapy 18 Pemetrexed 17 Cytarabine 17 Radiosurgery 16 Radiation 16 Doxorubicin 16 Bortezomib 16 atezolizumab 15 Prednisone 15 Etoposide 14 fludarabine 13 Lenalidomide 13

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01636128 2014-07-30

Urinary Biomarker Study With Sulindac and Difluoromethylornithine

Cancer Prevention Pharmaceuticals, Inc.

Phase 2 Withdrawn

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡